Objectives: Characterize baseline healthcare costs and degree of comorbidity and disease severity in RA patients, prior to initiating first-line treatment with the IV administered biologic agents abatacept or infliximab.
Method: Utilizing a large, managed care plan claims database, an analysis was conducted in adult RA patients during the 6 months prior to initiating first-line biologic treatment with abatacept or infliximab. The identification period was January 1, 2006 through August 31, 2010. Severity of overall comorbidity was described using Charlson Comorbidity Index (CCI) and all-cause health care costs, while RA-related healthcare costs were used as a proxy measure for severity of RA.
Result: A total of 1623 RA patients were identified who initiated abatacept or infliximab as first-line biologic therapy. Baseline RA-related healthcare costs for abatacept treated patients (n=411) were approximately twice those of patients treated with infliximab (n=1212). Baseline total all-cause health care costs and CCI were also significantly higher for abatacept treated patients (Table).
Conclusion: In a commercially insured population, those patients initiating first-line abatacept appeared to demonstrate greater baseline severity of RA, as well as more comorbidity than those who received first-line infliximab. Further research is required to better understand how pre-existing conditions and severity of RA impact selection of intravenous biologic therapy and subsequent response in this patient population.
Disclosure: T. Darkow, Bristol-Myers Squibb, 1, Bristol-Myers Squibb, 3 ; D. Trivedi, Bristol-Myers Squibb, 1, Bristol-Myers Squibb, 3 ; B. Meissner, Bristol-Myers Squibb, 1, Bristol-Myers Squibb, 3 ; L. Rosenblatt, Bristol-Myers Squibb, 1, Bristol-Myers Squibb, 3 ; T. Hebden, Bristol-Myers Squibb, 1, Bristol-Myers Squibb, 3 .